Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DM-1 is a synthetic curcumin analog that has demonstrated antitumor effects, particularly in the context of breast cancer treatment. It functions as an adjuvant in chemotherapy, enhancing the activity of other antitumor drugs like paclitaxel. DM-1 promotes apoptosis in tumor cells, with its mechanism primarily involving the activation of phosphorylated caspase 3, leading to reduced tumor growth, decreased tumor volume, and a significant reduction in metastasis. This action also contributes to a decrease in cachexia associated with tumors.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on DM-1.